Literature DB >> 25940075

Incremental and independent value of cardiopulmonary exercise test measures and the Seattle Heart Failure Model for prediction of risk in patients with heart failure.

Todd Dardas1, Yanhong Li2, Shelby D Reed2, Christopher M O'Connor2, David J Whellan3, Stephen J Ellis2, Kevin A Schulman2, William E Kraus2, Daniel E Forman4, Wayne C Levy5.   

Abstract

BACKGROUND: Multivariable risk scores and exercise measures are well-validated risk prediction methods. Combining information from a functional evaluation and a risk model may improve accuracy of risk predictions. We analyzed whether adding exercise measures to the Seattle Heart Failure Model (SHFM) improves risk prediction accuracy in systolic heart failure.
METHODS: We used a sample of patients from the Heart Failure and A Controlled Trial Investigating Outcomes of Exercise TraiNing (HF-ACTION) study (http://www.clinicaltrials.gov; unique identifier: NCT00047437) to examine the addition of peak oxygen consumption, expired volume per unit time/volume of carbon dioxide slope, 6-minute walk distance, or cardiopulmonary exercise duration to the SHFM. Multivariable Cox proportional hazards models were used to test the association between the combined end point (death, left ventricular assist device, or cardiac transplantation) and the addition of exercise variables to the SHFM.
RESULTS: The sample included 2,152 patients. The SHFM and all exercise measures were associated with events (all p < 0.0001) in proportional hazards models. There was statistically significant improvement in risk estimation when exercise measures were added to the SHFM. However, the improvement in the C index for the addition of peak volume of oxygen consumption (+0.01), expired volume per unit time/volume of carbon dioxide slope (+0.02), 6-minute walk distance (-0.001), and cardiopulmonary exercise duration (+0.001) to the SHFM was small or slightly worse than the SHFM alone. Changes in risk assignment with the addition of exercise variables were minimal for patients above or below a 15% 1-year mortality.
CONCLUSIONS: Exercise performance measures and the SHFM are independently useful for predicting risk in systolic heart failure. Adding cardiopulmonary exercise testing measures and 6MWD to the SHFM offers only minimal improvement in risk reassignment at clinically meaningful cut points.
Copyright © 2015 International Society for Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Seattle Heart Failure Model; exercise; heart failure; risk factors; risk prediction

Mesh:

Year:  2015        PMID: 25940075      PMCID: PMC4795804          DOI: 10.1016/j.healun.2015.03.017

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN: 1053-2498            Impact factor:   10.247


  29 in total

Review 1.  Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker.

Authors:  Margaret Sullivan Pepe; Holly Janes; Gary Longton; Wendy Leisenring; Polly Newcomb
Journal:  Am J Epidemiol       Date:  2004-05-01       Impact factor: 4.897

2.  Prognostic impact of the addition of peak oxygen consumption to the Seattle Heart Failure Model in a transplant referral population.

Authors:  Wayne C Levy; Keith D Aaronson; Todd F Dardas; Paula Williams; Jennifer Haythe; Donna Mancini
Journal:  J Heart Lung Transplant       Date:  2012-08       Impact factor: 10.247

Review 3.  Selection of cardiac transplantation candidates in 2010.

Authors:  Donna Mancini; Katherine Lietz
Journal:  Circulation       Date:  2010-07-13       Impact factor: 29.690

4.  Problems with risk reclassification methods for evaluating prediction models.

Authors:  Margaret S Pepe
Journal:  Am J Epidemiol       Date:  2011-05-09       Impact factor: 4.897

5.  Defining the optimal prognostic window for cardiopulmonary exercise testing in patients with heart failure.

Authors:  Ross Arena; Jonathan Myers; Joshua Abella; Sherry Pinkstaff; Peter Brubaker; Dalane Kitzman; Mary Ann Peberdy; Daniel Bensimhon; Paul Chase; Daniel E Forman; Marco Guazzi
Journal:  Circ Heart Fail       Date:  2010-03-03       Impact factor: 8.790

6.  Heart failure prognostic models: why bother?

Authors:  Keith D Aaronson; Jennifer Cowger
Journal:  Circ Heart Fail       Date:  2012-01       Impact factor: 8.790

7.  Application of the Seattle Heart Failure Model in ambulatory patients presented to an advanced heart failure therapeutics committee.

Authors:  Eiran Z Gorodeski; Eric C Chu; Chen H Chow; Wayne C Levy; Eileen Hsich; Randall C Starling
Journal:  Circ Heart Fail       Date:  2010-08-26       Impact factor: 8.790

8.  Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial.

Authors:  Christopher M O'Connor; David J Whellan; Kerry L Lee; Steven J Keteyian; Lawton S Cooper; Stephen J Ellis; Eric S Leifer; William E Kraus; Dalane W Kitzman; James A Blumenthal; David S Rendall; Nancy Houston Miller; Jerome L Fleg; Kevin A Schulman; Robert S McKelvie; Faiez Zannad; Ileana L Piña
Journal:  JAMA       Date:  2009-04-08       Impact factor: 56.272

9.  Reproducibility of peak oxygen uptake and other cardiopulmonary exercise testing parameters in patients with heart failure (from the Heart Failure and A Controlled Trial Investigating Outcomes of exercise traiNing).

Authors:  Daniel R Bensimhon; Eric S Leifer; Stephen J Ellis; Jerome L Fleg; Steven J Keteyian; Ileana L Piña; Dalane W Kitzman; Robert S McKelvie; William E Kraus; Daniel E Forman; Andrew J Kao; David J Whellan; Christopher M O'Connor; Stuart D Russell
Journal:  Am J Cardiol       Date:  2008-07-09       Impact factor: 2.778

10.  Utility of the Seattle Heart Failure Model in patients with advanced heart failure.

Authors:  Andreas P Kalogeropoulos; Vasiliki V Georgiopoulou; Grigorios Giamouzis; Andrew L Smith; Syed A Agha; Sana Waheed; Sonjoy Laskar; John Puskas; Sandra Dunbar; David Vega; Wayne C Levy; Javed Butler
Journal:  J Am Coll Cardiol       Date:  2009-01-27       Impact factor: 24.094

View more
  6 in total

1.  An Appraisal of Biomarker-Based Risk-Scoring Models in Chronic Heart Failure: Which One Is Best?

Authors:  Barbara S Doumouras; Douglas S Lee; Wayne C Levy; Ana C Alba
Journal:  Curr Heart Fail Rep       Date:  2018-02

2.  Optimal Endpoints of Acute Heart Failure Therapy.

Authors:  Jessica H Huston; Robinson Ferre; Peter S Pang; Ovidiu Chioncel; Javed Butler; Sean Collins
Journal:  Am J Ther       Date:  2018 Jul/Aug       Impact factor: 2.688

3.  Is cardiopulmonary exercise testing essential to indicate ventricular assist device implantation in patients with INTERMACS profile 4-7?

Authors:  Teruhiko Imamura; Koichiro Kinugawa; Daisuke Nitta; Osamu Kinoshita; Kan Nawata; Minoru Ono
Journal:  J Artif Organs       Date:  2016-03-18       Impact factor: 1.731

4.  Beta-blockers in heart failure prognosis: Lessons learned by MECKI Score Group papers.

Authors:  Gaia Cattadori; Silvia Di Marco; Stefania Farina; Giuseppe Limongelli; Emanuele Monda; Roberto Badagliacca; Silvia Papa; Lucia Tricarico; Michele Correale
Journal:  Eur J Prev Cardiol       Date:  2020-12       Impact factor: 7.804

Review 5.  Comparison among different multiparametric scores for risk stratification in heart failure patients with reduced ejection fraction.

Authors:  Ugo Corrà; Alessandra Magini; Stefania Paolillo; Maria Frigerio
Journal:  Eur J Prev Cardiol       Date:  2020-12       Impact factor: 7.804

6.  Feasibility of Serial 6-min Walk Tests in Patients with Acute Heart Failure.

Authors:  Sean P Collins; Michael Thorn; Richard M Nowak; Phillip D Levy; Gregory J Fermann; Brian C Hiestand; Tillman Douglas Cowart; Robert P Venuti; William R Hiatt; ShiYin Foo; Peter S Pang
Journal:  J Clin Med       Date:  2017-09-11       Impact factor: 4.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.